Annexon Inc Ordinary Shares ANNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
-
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
-
Annexon to Participate in Upcoming September Investor Conferences
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
-
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
-
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
-
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Trading Information
- Previous Close Price
- $3.41
- Day Range
- $3.44–4.03
- 52-Week Range
- $2.54–7.18
- Bid/Ask
- $4.05 / $4.09
- Shares Outstanding
- 189.58M
- Market Cap
- $760.21M
- Volume/Avg
- 6M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 92
- Website
- https://www.annexonbio.com
Valuation
|
Metric
|
ANNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.76 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANNX
|
|---|---|
Quick Ratio | 5.44 |
Current Ratio | 5.53 |
Interest Coverage | — |
Quick Ratio
ANNX
Profitability
|
Metric
|
ANNX
|
|---|---|
Return on Assets (Normalized) | −72.86% |
Return on Equity (Normalized) | −96.89% |
Return on Invested Capital (Normalized) | −88.91% |
Return on Assets
ANNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^!$$$< | LOCK|@!!C | $127B | |||
| Moderna Inc
MRNA
| LOCK|v<B<kx% | LOCK|>Y> | $91B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%MHQ>>$ | LOCK|q^BF | $81B | |||
| argenx SE ADR
ARGX
| LOCK|TN%bdt& | LOCK|#<& | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|d$>stDM | LOCK|^s | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^<S!^G% | LOCK|??&k | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^STlLNv< | LOCK|pX^g$ | $27B | |||
| Incyte Corp
INCY
| LOCK|$YfZf^! | LOCK|@jm | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#x>$DR | LOCK|T%D | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|y^H<Y!# | LOCK|n@? | $14B |
United States